An interventional study of LUTONIX 035 Drug Coated Balloon PTA Catheter in Arteriovenous Fistula, sponsored by C. R. Bard. Active, not recruiting at 26 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-18.
Sponsored by C. R. Bard (part of Becton, Dickinson and Company) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Arteriovenous Fistula by Becton, Dickinson and Company — 1 open to participants now, 2 under way, none of them phase 3. Arteriovenous Fistula · Becton, Dickinson and Company.
Among the 10 studies in Arteriovenous Fistula by Becton, Dickinson and Company, this one is the only one that started in 2018, is one of 8 with no phase, and was the 7th registered.
248 studies on the registry are indexed under Arteriovenous Fistula; 44 are open to participants now.
Browse Arteriovenous Fistula studies →1 of the 10 studies in Arteriovenous Fistula by Becton, Dickinson and Company is open now, in 2 countries. Recruiting first, the newest first:
C. R. Bard · Sites in United States, Australia
Ages 18+
By country, each count listing its studies:
Of the 27 Arteriovenous Fistula studies recruiting now, 13 (48%) set no upper age limit and 4 (15%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2018.
This study's planned enrollment of 213 is above the median of 64 across 166 interventional studies indexed under Arteriovenous Fistula.
Median enrollment 100 across the 9 interventional studies, 320 across the 1 observational. Of the 8 that completed or were terminated, 3 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under C. R. Bard, one of the names counted as Becton, Dickinson and Company. Under that name alone:
C. R. Bard is the lead sponsor of 117 studies on the registry; 6 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 13 (76%) have results posted.
2 of the studies in Arteriovenous Fistula by Becton, Dickinson and Company that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03506308C. R. BardPost Approval Study Investigating Lutonix Drug Coated Balloon for Treatment of Dysfunctional Arteriovenous Fistulae | 2027-04 |
| NCT04634916C. R. BardPost-market Surveillance Study of the BD® WavelinQ™ EndoAVF System | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies in Arteriovenous Fistula by Becton, Dickinson and Company, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This prospective, global, multicenter, single arm post-approval study is designed to investigate the clinical use and safety of the Lutonix® 035 AV Drug Coated Balloon (DCB) PTA Catheter in subjects presenting with clinical and hemodynamic abnormalities in native arteriovenous (AV) fistulae located in the upper extremity.
This post-market approval study (PAS) is required by the FDA as a condition of approval for the Lutonix drug coated balloon catheter. It is intended to demonstrate safety and assess the clinical use and outcomes of the LUTONIX Catheter in dysfunctional arteriovenous fistulae (AVF) in a heterogeneous patient population in real world clinical practice.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Successful pre-dilation of the target lesion with an uncoated percutaneous transluminal angioplasty (PTA) balloon defined as:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This is a single-arm study. All subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
Device: LUTONIX 035 Drug Coated Balloon PTA Catheter
All subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
Percentage of Participants With Target Lesion Primary Patency (TLPP)
TLPP is defined as the interval following index procedure intervention until clinically driven reintervention of the target lesion or access thrombosis.
Time frame: 6 Months
Percentage of Participants With No Primary Safety Events
Primary safety events include any serious adverse event(s) involving the AV access circuit through 30 days
Time frame: 30 days
Percentage of Participants With Target Lesion Primary Patency
TLPP is defined as the interval following index procedure intervention until clinically driven reintervention of the target lesion or access thrombosis.
Time frame: 12, 18, 24 Months
Number of re-interventions required to maintain target lesion patency
Clinically driven reintervention is defined as a lesion that has ≥ 50% stenosis and at least one clinical, physiological or hemodynamic abnormality attributable to the stenosis defined in the K/DOQI guidelines.
Time frame: 6, 12, 18, 24 Months
Percentage of Participants With Access Circuit Primary Patency (ACPP)
Access circuit is defined as the area from the AV access anastomosis to the superior vena cava-right atrial junction.
Time frame: 6, 12, 18, 24 Months
Number of re-interventions required to maintain access circuit patency
Clinically driven reintervention is defined as a lesion that has ≥ 50% stenosis and at least one clinical, physiological or hemodynamic abnormality attributable to the stenosis defined in the K/DOQI guidelines.
Time frame: 6, 12, 18, 24 Months
Percentage of Participants With Device, Procedural, and Clinical Success
Device Success: Successful delivery to the target lesion, deployment, and retrieval at index procedure. Procedural Success: At least one indicator of hemodynamic success (e.g., physical examination with restoration of a thrill, direct measurement of flow) in the absence of peri-procedural (index procedure and through hospital stay) Serious Adverse Device Effects (SADEs). Clinical Success: The resumption of dialysis for at least one session after the index procedure.
Time frame: 24 Months
Percentage of Participants With Abandonment of Permanent Access in the Index Extremity
The arteriovenous fistula / access circuit is considered abandoned when it is no longer being used for dialysis because the access was not functioning.
Time frame: 6, 12, 18, 24 Months
Percentage of Participants With Secondary Patency of the Access Circuit
Survival of patency of access circuit from the time of intervention until access abandonment or achievement of a censored event (death, transfer to another hemodialysis unit, transfer to peritoneal dialysis, transplantation, and end of study period), and includes all surgical and endovascular interventions.
Time frame: 6, 12, 18, 24 Months
Time to loss of target lesion secondary patency following DCB intervention
Time between first reintervention with the DCB to the next loss of patency
Time frame: 24 Months
Percentage of Participants With Freedom from any Serious Adverse Event(s) Involving the AV Access Circuit
Safety events include any serious adverse event(s) involving the AV access circuit
Time frame: 6, 12, 18, 24 Months
Percentage of Participants With Device and Procedure Related Adverse Events
Freedom from device-related or procedure-related serious adverse events
Time frame: 6, 12, 18, 24 Months
Vital status of participants
All cause death
Time frame: 36, 48, and 60 Months
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2018 (actual). Primary completion is estimated for Apr 2027, 104 months after the start.
Of 84 interventional studies with no phase under Arteriovenous Fistula, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 43. This study's planned 104 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.